Handelsbanken Fonder’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.27M Buy
10,358
+1,900
+22% +$448K 0.01% 632
2026
Q1
$1.69M Buy
8,458
+2,100
+33% +$415K 0.01% 806
2025
Q4
$1.2M Hold
6,358
﹤0.01% 956
2025
Q3
$1.13M Hold
6,358
﹤0.01% 961
2025
Q2
$723K Sell
6,358
-300
-5% -$32.1K ﹤0.01% 1092
2025
Q1
$700K Buy
6,658
+800
+14% +$90.5K ﹤0.01% 1097
2024
Q4
$628K Buy
5,858
+500
+9% +$56.5K ﹤0.01% 1196
2024
Q3
$536K Buy
5,358
+500
+10% +$50.3K ﹤0.01% 1211
2024
Q2
$409K Buy
4,858
+1,200
+33% +$95.5K ﹤0.01% 1243
2024
Q1
$267K Hold
3,658
﹤0.01% 1426
2023
Q4
$261K Hold
3,658
﹤0.01% 1433
2023
Q3
$219K Hold
3,658
﹤0.01% 1437
2023
Q2
$264K Buy
+3,658
New +$274K ﹤0.01% 1396
2022
Q3
Sell
-5,062
Closed -$282K 1575
2022
Q2
$282K Hold
5,062
﹤0.01% 1360
2022
Q1
$355K Hold
5,062
﹤0.01% 1422
2021
Q4
$488K Buy
5,062
+962
+23% +$88.9K ﹤0.01% 1366
2021
Q3
$356K Hold
4,100
﹤0.01% 1533
2021
Q2
$336K Buy
4,100
+320
+8% +$26.6K ﹤0.01% 1594
2021
Q1
$359K Sell
3,780
-2,404
-39% -$227K ﹤0.01% 1367
2020
Q4
$384K Hold
6,184
﹤0.01% 1294
2020
Q3
$368K Hold
6,184
﹤0.01% 1145
2020
Q2
$432K Buy
+6,184
New +$392K ﹤0.01% 1029

Other funds holding LGND

Handelsbanken Fonder's LGND Position: Q2 2026 in Review

Handelsbanken Fonder increased its Ligand Pharmaceuticals (LGND) stake by 22% in Q2 2026, buying an estimated $448K and bringing the position to 10,358 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #632.

Handelsbanken Fonder first reported a position in LGND in Q2 2020 and has held it in 22 quarters since. 168 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Handelsbanken Fonder held 10,358 shares of Ligand Pharmaceuticals worth $3.27M as of Q2 2026.
  • Handelsbanken Fonder bought 1,900 Ligand Pharmaceuticals shares in Q2 2026, an estimated $448K.
  • Ligand Pharmaceuticals made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #632 holding.
  • Handelsbanken Fonder first reported a position in Ligand Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 168 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.